



Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D. C. 20231 www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLIC	CANT	ATTY. DOCKET NO.
09/856050	UEMURA	Н	UEMURA 8
		INTERNATIONA	L APPLICATION NO.
BROWDY AND NEIMARK 624 NINTH STREET N W SUITE 300		РСТ/ЈЕ	299/06474
WASHINGTON, DC 20001		I.A. FILING DATE	PRIORITY DATE
		19 NOV 99	20 NOV 98
NOTHING		DATE MAILED:	20 JUN 2001
NOTIFICATION OF MIS	SSING REQUIREMENTS U	NDER 35 U.S.C. 371 I	N THE UNITED
	DESIGNATED/ELECTED (abmitted by the applicant or the IB to		Tdt-
Office as a Designated C	Office (37 CFR 1.494) an Electer	d Office (37 CFR 1.495):	Trademark
U.S. Basic National Fed	e. Indication of Sr	mall Entity Status.	
Copy of the international		the international application in	
Oath or Declaration of		Article 19 amendments into Er	nglish.
Copy of Article 19 ame	ndments Other:		
Priority Document.  The International Prelin	ninary Examination Report in English	and its Anneves if any	
	to the International Preliminary Exam		
Applicant has requested early the indicated items in paragraph 3 be prior to 20 or 30 months from the prior to 20. S. Basic National Fee		ut has not filed the following is ecopy of the international app emational application.	ndicated items and/or lication must be filed
3. The following items <b>MUST</b> be fu acceptance under 35 U.S.C. 371:	urnished within the period set forth be	clow in order to complete the	requirements for
	olication into English. A processing f	fee will be required if submitte	ed
later than the appro	opriate 20 or 30 months from the prio	ority date.	
The current transla Translation.	ation is defective for the reasons indic	ated on the attached Notice of	Defective
	oviding the translation of the applicati	ion and/or the Annexes later t	han the
L	30 months from the priority date (37 (		
<u> </u>	f the inventors, in compliance with 37		
	eferably by the International application		
date.	required if submitted later than the app	propriate 20 or 30 months from	m the priority
The current oath or	r declaration does not comply with 37	7 CFR 1.497(a) and (b) for the	reasons
	ached PCT/DO/EO/917.	h	
priority date (37 C	ing the oath or declaration later than t	ne appropriate 20 or 30 mont	ns from the
4. Additional claim fees of \$	as a   large entity   small	entity, including any required	l multiple dependent
claim fee, are required. Applicant m due (37 CFR 1.492(g)). See attached	ust submit the additional claim fees o		•
5. Applicant has not submitted the PCT/DO/EO/920.	e required sequence listing pursuant to	o 37 CFR 1.821-1.825. See	attached
MONTHS FROM THE DATE OF	H IN 3(a)-3(d), 4 AND 5 ABOVE M THIS NOTICE OR BY 22 OR 32 N APPLICATION, WHICHEVER I ANDONMENT.	MONTHS (where 37 CFR 1.	495 applies) FROM
The time period set above may be ext 1.136(a).	sended by filing a petition and fee for	extension of time under the p	rovisions of 37 CFR
6. If box 3a or 3c is checked, a trans Annexes will be cancelled. A proces 7. The Article 19 amendments are or 30 (37 CFR 1.495(d)) months from	sing fee will be required if submitted e cancelled since a translation was not	later than 20 or 30 months fro	om the priority date.
Applicant is reminded that any commaddress given in the heading and inclu			e mailed to the
A come of	his notice MT/ST he satur	and with this second	•
Enclosed: PCT/DO/EO/917	his notice MUST be return   Notice of Defective Transi	<i>lation</i>	·•
= PTO-875	PCT/DO/EO/920		d )
	<u> </u>	Vonda M. Wallace	$\mathcal{M}$
FORM PCT/DO/EO/905 (March 200	(1) Telep	phone: 703-305-3736	



Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NO.	FIRST NAMED APPLICANT		ATTY. DOCKET NO.
09/856050	UEMURA	Н	UEMURA 8
		INTERNATIONAL APPLICATION NO.	
BROWDY AND NEIMARK 324 NINTH STREET N W SUITE 300		PCT/JP99/06474	
WASHINGTON, DC 20001		I.A. FILING DATE	PRIORITY DATE
		19 NOV 99	20 NOV 98

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

Telephone: 703-305-3736

FORM PCT/DO/EO/920 (March 2001)